RxDoctor Payments Data

Juan Orozco, MD

Family Medicine · Miami, FLNPI 1255598009

Payments from drug & device makers

$46,641in general payments, 2019–2025

Across 90 payments — averaging $518.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$45K
  • Lilly USA, LLC$486
  • Amgen$184
  • Novo Nordisk$129
  • AstraZeneca$121
  • Amarin Pharma, Inc.$87
  • plus $549 from 15 others

What the payments were for

  • Food & beverage$1,556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$46,641 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$33,144
Medicare patients
77
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide190$214,224
OzempicSemaglutide186$181,914
EliquisApixaban133$133,567
JardianceEmpagliflozin103$92,967
JanuviaSitagliptin Phosphate40$60,393
FarxigaDapagliflozin Propanediol54$54,838
RybelsusSemaglutide20$34,070
ProliaDenosumab14$24,395
XareltoRivaroxaban14$21,350
TradjentaLinagliptin12$14,787
EntrestoSacubitril/Valsartan13$14,669
Breo ElliptaFluticasone/Vilanterol25$10,303
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$4,817
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro17$4,747
Levothyroxine Sodium415$4,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$129$215,984206 claims
Lilly USA, LLCMounjaro$486$214,224190 claims
AstraZenecaFarxiga$121$54,83854 claims
AmgenProlia$184$24,39514 claims
Johnson & JohnsonXarelto$50$21,35014 claims
AbbVieSynthroid$42$3,80728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →